Keith Stokes+FollowOncologists: GIST Tips You Need to KnowIf you’re a community oncologist who only sees a handful of GIST cases, here’s the scoop: experts say nailing your molecular testing and knowing when to refer patients to a specialist can make all the difference. Don’t just go with the flow—get strategic about treatment sequencing and don’t hesitate to loop in a specialized center when things get tricky. These practical tips could seriously level up your patient care! #Oncology #GIST #CancerCare #MedicalTips #Healthcare #Health70Share
shermandarlene+FollowICG Dye Could Change Vulvar Cancer CareBig news for vulvar cancer treatment: indocyanine green (ICG) dye is matching the gold-standard dual tracers for finding sentinel lymph nodes, but with way less hassle. Researchers reviewed 88 studies and found ICG’s detection rates are just as good as the usual technetium-99m plus blue dye combo. This could mean fewer logistics and smoother surgeries. SPIO tracers also look promising, but need more research. Could we be seeing a new standard for SLN mapping soon? #VulvarCancer #MedicalResearch #CancerCare #WomensHealth #Oncology #Health51Share
Charles Christensen+FollowHER3: The Comeback Kid in Cancer ResearchTurns out HER3, once thought to be a benchwarmer in cancer, is actually a major player! Scientists now say HER3 helps tumors survive and resist treatment, especially in breast and lung cancers. The catch? Not all patients benefit from HER3-targeted drugs—only those with active HER3 signaling. New antibody-drug combos are showing promise, but matching the right patients is key. HER3 might finally get its moment as a precision cancer therapy superstar! #CancerResearch #HER3 #PrecisionMedicine #Oncology #MedicalBreakthrough #Health01Share
james60+FollowGame-Changer for Nose Cancer Care?Just saw this update from ESTRO2025—Maria Concetta La Milia and her team dropped new research on nose vestibule interventional radiotherapy (aka brachytherapy). The coolest part? Patients themselves say this treatment keeps things working better and is less harsh than the usual options. Love seeing patient voices actually shape cancer care! Curious to see if this becomes the new go-to for head and neck cancers. #ESTRO2025 #Oncology #Brachytherapy #PatientCare #ESTRO2025 #Oncology #Brachytherapy #PatientCare #Health50Share
Michelle Welch+FollowFirst-Ever FDA-Approved LGSOC Treatment!Big news for the ovarian cancer community: the FDA just approved the first-ever treatment specifically for KRAS-mutated recurrent low-grade serous ovarian cancer! AVMAPKI FAKZYNJA CO-PACK is a new combo therapy that’s shown real promise in clinical trials, finally giving hope to patients who had zero targeted options before. This is a huge milestone for a rare cancer that mostly affects younger women and is notoriously tough to treat. Could this be a game-changer for cancer care? #CancerBreakthrough #OvarianCancer #FDAApproval #MedicalNews #Oncology #Health00Share
Brandy Larson+FollowFrom Med School to ASCO Main Stage!İmdat Eroğlu just landed a major speaking spot at ASCO25, the biggest oncology congress out there! He’s sharing his team’s research on a global stage, and you can feel how pumped he is. Major shoutout to his mentors and colleagues for all the support—proof that good guidance goes a long way. Imagine going from med school to presenting at the top conference in your field! #ASCO25 #Oncology #MedicalResearch #CareerGoals #Mentorship #Health00Share
Michelle Welch+FollowImmunotherapy Flop in Colon Cancer?The ATOMIC trial just dropped some surprising news: adding atezolizumab (an immunotherapy) to standard chemo didn’t really help prevent stage III MSI-H/dMMR colon cancer from coming back. While it worked wonders in metastatic cases, it didn’t move the needle much here—except maybe for a few high-risk folks. The combo was safe, though! Looks like chemo alone is still the go-to, but researchers are eyeing new strategies like neoadjuvant immunotherapy and ctDNA tracking. Stay tuned for what’s next! #ColonCancer #Immunotherapy #ATOMICTrial #Oncology #CancerResearch #Health60Share
April Anderson+FollowGame-Changer for Tough Lymphomas?Just read about a new treatment combo that could seriously boost survival for people with aggressive T- and NK-cell lymphomas. Researchers found that using small-molecule inhibitors first, then epigenetic modifiers, worked way better than old-school chemo for those who relapsed. The difference was especially huge for high-risk patients! It’s wild how switching up the order of meds could make such a big impact. Could this be the new standard for tough-to-treat blood cancers? #CancerResearch #Lymphoma #MedicalBreakthrough #Oncology #HealthNews #Health20Share
Jacqueline Howard DDS+FollowBladder Cancer Breakthrough: No 90-Day Deaths!Big news for advanced bladder cancer: a combo of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) before surgery led to zero 90-day deaths and a whopping 60% complete response rate in a recent study. Even patients who couldn’t get cisplatin saw great results. Plus, survival rates with this treatment are way better than standard chemo. Feels like a game-changer for urothelial cancer! #BladderCancer #CancerResearch #MedicalBreakthrough #UrothelialCancer #Oncology #Health366Share
Ryan Lewis+FollowCancer Breakthrough Lasts Nearly 4 Years!UroGen just dropped some wild data: their JELMYTO treatment for a rare urinary tract cancer is keeping patients cancer-free for almost four years on average! Even better, it works whether the cancer is new or coming back. This is the first FDA-approved non-surgical option for this cancer, and the results are so strong that analysts are hyped on the stock. Biotech is seriously having a moment, and this could be a game-changer for patients who want to avoid surgery. #CancerBreakthrough #BiotechNews #UroGen #CancerResearch #Oncology #MedicalInnovation #Health2869Share
